Stockscreener 앱 받기
0.406
4.10%
0.016
시간 외 거래:
.40
-0.006
-1.48%
전일 마감가:
$0.39
열려 있는:
$0.4
하루 거래량:
689.56K
Relative Volume:
0.18
시가총액:
$5.04M
수익:
$11.51M
순이익/손실:
$-54.00M
주가수익비율:
-0.0111
EPS:
-36.5591
순현금흐름:
$-23.73M
1주 성능:
-0.85%
1개월 성능:
-19.28%
6개월 성능:
-79.03%
1년 성능:
-91.43%
1일 변동 폭
$0.3751
$0.4162
1주일 범위
$0.3401
$0.4498
52주 변동 폭
$0.313
$14.07
재규어 헬스 Stock (JAGX) Company Profile
명칭
Jaguar Health Inc
전화
415-371-8300
주소
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
0.406 | 4.58M | 11.51M | -54.00M | -23.73M | -36.56 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
재규어 헬스 Stock (JAGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-07-11 | 개시 | Rodman & Renshaw | Buy |
재규어 헬스 주식(JAGX)의 최신 뉴스
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Bitget
Jaguar Health plans AI use for rare disease drug development By Investing.com - Investing.com Australia
Jaguar Health (JAGX) Enhances Development with AI Technology - GuruFocus
Macro Review: Is Jaguar Health Inc gaining market share2026 Big Picture & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Jaguar Health plans AI use for rare disease drug development - Investing.com
No-treatment pediatric disorder drives Jaguar's AI push for crofelemer - Stock Titan
Jaguar Health Inc (JAGX) Q4 2025 Earnings Call Highlights: Reven - GuruFocus
Earnings call transcript: Jaguar Health Q4 2025 misses EPS, revenue targets By Investing.com - Investing.com South Africa
Earnings call transcript: Jaguar Health Q4 2025 misses EPS, revenue targets - Investing.com India
JAGX: Q4 2025 revenue up 5% sequentially; major out-license deal secures $16M for rare disease focus - TradingView — Track All Markets
JAGX Stock Chart | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health to Host Investor Webcast on Q4 2025 Financials - National Today
Jaguar Health, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing (April 2026) - Minichart
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - ACCESS Newswire
Jaguar Health reports improved stockholders’ equity after recent transactions - Investing.com
Jaguar Health reports improved stockholders’ equity after recent transactions By Investing.com - Investing.com South Africa
Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions - TipRanks
Jaguar Health says equity rebuilt above Nasdaq minimum after financing, inventory and debt adjustments - TradingView — Track All Markets
Jaguar Health (NASDAQ: JAGX) details equity boost after deficit - Stock Titan
Investment Recap: Is Jaguar Health Inc stock a top performer YTDWeekly Loss Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Jaguar Health completes diarrhea study in dogs on chemo By Investing.com - Investing.com Canada
Jaguar Health (JAGX) Advances Canalevia-CA1 Study for Chemothera - GuruFocus
Jaguar Health completes diarrhea study in dogs on chemo - Investing.com
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Dog cancer-treatment diarrhea drug nears FDA filing after trial - Stock Titan
JAGX Fundamental Analysis & Valuation | Fair Value & Financial Strength | JAGUAR HEALTH INC (NASDAQ:JAGX) - ChartMill
Jaguar Health (JAGX.US) will release its earnings report before the market opens on April 10. - 富途牛牛
Jaguar Health, Inc. (JAGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Jaguar Health Reports 2025 Financials - marketscreener.com
JAGX Sees Slight Revenue Decline Amid Decrease in Mytesi Prescri - GuruFocus
Jaguar Health Reports 2025 Financial Results: 5% Q4 Revenue Growth, $16M Up-Front License Deal, and Nasdaq Compliance Appeal 1 - Minichart
Wider 2025 loss, $16M Future Pak deal and Nasdaq risk for Jaguar Health (JAGX) - Stock Titan
Jaguar lands $16M license payment as Nasdaq delisting is stayed - Stock Titan
Jaguar Health, Inc. 2025 Annual Report: Key Financials, Agreements, and Business Segment Highlights - Minichart
Jaguar Health 2025 10-K: $11.51M Revenue, ($22.97) EPS - TradingView — Track All Markets
Jaguar Health (NASDAQ: JAGX) leans into rare GI drugs and $16M Mytesi deal - Stock Titan
Day Trade: Is Jaguar Health Inc stock showing strong momentumRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Rate Cut: Will Jaguar Health Inc benefit from AI trends2026 Trading Volume Trends & Low Risk Entry Point Tips - baoquankhu1.vn
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress - ACCESS Newswire
JAGX Q4'25 Earnings: EPS estimate is (4.26) USD - TradingView — Track All Markets
Children needing IV nutrition cut support 12%-37% in crofelemer study - Stock Titan
Jaguar Health Delays Annual Form 10-K Filing - TipRanks
Jaguar Health (NASDAQ: JAGX) notifies SEC of late 10-K; will file within 15 days - Stock Titan
Jaguar Health Inc. (JAGX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
JAGX Q4'25 Earnings: revenue estimate is 4.21M USD - TradingView
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Central New Jersey News
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - burlingtonfreepress.com
Published on: 2026-03-29 01:23:24 - baoquankhu1.vn
Jaguar Health Inc Stock: Commercial-Stage Pharma Targeting Gastrointestinal Disorders in Humans and - AD HOC NEWS
Entry Recap: Is Jaguar Health Inc undervalued by DCF analysisAnalyst Upgrade & Low Risk High Reward Ideas - baoquankhu1.vn
Jaguar Health Inc stock faces extreme dilution risk as proxy seeks massive share increase and dual r - AD HOC NEWS
재규어 헬스 (JAGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
자본화:
|
볼륨(24시간):